Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Cantor Fitzgerald
McKesson
QuintilesIMS
Citi
Medtronic
Boehringer Ingelheim
Mallinckrodt

Generated: December 17, 2018

DrugPatentWatch Database Preview

Litigation Details for Aventis Pharma Deutschland GMBH v. Lupin Ltd. (E.D. Va. )

« Back to Dashboard

Small Molecule Drugs cited in Aventis Pharma Deutschland GMBH v. Lupin Ltd.
The small molecule drug covered by the patents cited in this case is ➤ Try a Free Trial .

Details for Aventis Pharma Deutschland GMBH v. Lupin Ltd. (E.D. Va. )

Date Filed Document No. Description Snippet Link To Document
2006-07-17 234 Schering’s ‘258 Patent On May 6, 1986, Schering’s Patent No. 4,587,258 (the ‘258 patent or “Gold patent… U.S. Patent Application No. 635,390, which eventually issues into U.S. Patent No. 4,587,258 (the ‘… of contention involves United States Patent No. 4,587,258, which Aventis licensed from Schering and…for being “anticipated by Gold U.S. 4,587,258” (the ‘258 patent). Id. at LUPRAM 000269-270. The Examiner… enough, the ‘722 patent is a subsequent patent to a patent known as the ‘258 patent, which was approved External link to document
2005-12-02 37 Aventis owns U.S. Patent No. 5,061,722, known as the “ ‘722 patent.” The ‘722 patent involves a pharmaceutical… drug claimed in a patent or the use of which is claimed in a patent, . . . if the…product claimed in a patent or the use of which is claimed in a patent before the expiration… the “pioneer” patent. Id. In this case, Lupin Ltd. certified that Plaintiffs’ patent “is invalid or …SCHWARTZ, HERBERT , PATENT LAW AND PRACTICE , §3.V.A. (4th. Ed. 2003)[hereinafter “Patent Law and Practice External link to document
2006-01-18 46 Aventis owns U.S. Patent No. 5,061,722, known as the “‘722 patent.” The ‘722 patent involves a pharmaceutical…status of the “pioneer” patent, Lupin Ltd. certified that Plaintiffs’ patent “is invalid or will not …‘722 patent, constitutes infringement of one or more of the claims of that patent under…‘722 patent under 35 U.S.C. § 271(b) by actively inducing Lupin Ltd. to infringe the ‘722 patent.” Id…developing a generic version of a patented drug before the patent has expired, and 2) provide the innovative External link to document
2006-05-11 93 . That proceeding involved U.S. Patent No. 4,587,258 (the ‘258 patent) and the parent ‘284 application….S. Patent No. 5,061,722 (the ‘722 patent), which was issued on October 29, 1991. The ‘722 patent covers…relating to the status of the ‘722 patent, Lupin certified that Aventis’ patent “is invalid or will not be infringed…SCHWARTZ, PATENT LAW AND PRACTICE § 5.I (4th ed. 2003). “It is a ‘bedrock’ principle of patent law that… 20: 19. As MOY ’S WALKER ON PATENTS explains: Two patent claims can be dominant and subservient External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Cipla
Boehringer Ingelheim
Federal Trade Commission
Teva
Deloitte
Covington
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.